Prab: CSV import

2025-03-22T19:24:56Z

CSV import

← Older revision		Revision as of 19:24, 22 March 2025
Line 1:		Line 1:
	[[~~File:~~Fotemustine.svg\|~~thumb~~\|~~Fotemustine]]~~		{{Short description\|A chemotherapy drug used in the treatment of certain cancers}}
	== ~~Fotemustine: Therapeutic Role and Clinical Considerations~~ ==		{{Drugbox
	'''Fotemustine''' stands as a notable chemotherapeutic agent in the landscape of melanoma treatments, particularly for metastatic melanoma, one of the most aggressive and challenging forms of skin cancer. Classified as a [[nitrosourea alkylating agent]], fotemustine has drawn interest in the European medical community for its therapeutic potential, although it remains unapproved by the [[United States Food and Drug Administration\|~~U.S. FDA]]~~.		\| Verifiedfields = changed
			\| verifiedrevid = 477241123
			\| IUPAC_name = Ethyl 3,3-dimethyl-2-oxo-2-[[3-(2-chloroethyl)-3-nitrosoureido]oxy]propanoate
			\| image = Fotemustine.svg
			\| width = 200px
			\| tradename = Muphoran
			\| legal_status = Rx-only
			\| routes_of_administration = Intravenous
			\| ATC_prefix = L01
			\| ATC_suffix = AD05
			\| CAS_number = 92118-27-9
			\| PubChem = 45867
			\| DrugBank = DB04154
			\| ChemSpiderID = 41695
			\| UNII = 1Y1L2U4VEB
			\| KEGG = D04101
			\| ChEMBL = 1201185
			\| C=9
			\| H=19
			\| Cl=1
			\| N=3
			\| O=5
			\| molecular_weight = 289.72 g/mol
			}}

	~~=== Mechanism~~ of ~~Action ===~~		'''Fotemustine''' is a [[chemotherapy]] drug used primarily in the treatment of [[malignant melanoma]] and certain types of [[brain tumors]]. It belongs to the class of [[alkylating agents]], which work by adding an alkyl group to the DNA of cancer cells, thereby interfering with their ability to multiply.

	As a nitrosourea ~~alkylating agent~~, ~~fotemustine~~ exerts its ~~cytotoxic~~ effects by ~~causing~~ DNA ~~damage. Specifically~~, ~~it facilitates the formation of~~ cross-~~links~~ in DNA~~, hindering its~~ replication and ~~transcription~~, ~~thereby inhibiting~~ the ~~proliferation of malignant cells<ref>Review article on the mechanism of nitrosourea alkylating agents</ref>~~.		==Mechanism of Action==
			Fotemustine is a [[nitrosourea]] compound, similar to other drugs in its class such as [[carmustine]] and [[lomustine]]. It exerts its antitumor effects by alkylating the DNA of cancer cells, leading to [[DNA cross-linking]] and strand breaks. This ultimately results in the inhibition of DNA replication and cell division, causing cell death. The drug is particularly effective in crossing the [[blood-brain barrier]], making it useful in treating [[brain tumors]].

	=== Clinical ~~Efficacy and Comparisons =~~==		==Clinical Use==
			Fotemustine is primarily indicated for the treatment of [[metastatic melanoma]], especially when the cancer has spread to the brain. It is also used in the management of [[glioblastoma]] and other high-grade [[gliomas]]. The drug is administered intravenously, typically in a hospital setting, due to its potential side effects and the need for careful monitoring.

	~~Fotemustine's clinical worth has been explored in comparative studies with other established treatments for metastatic melanoma. A prominent study<ref name~~=~~"study1">~~[2]~~</ref> revealed the following insights:~~		==Side Effects==
	* '''Response Rates''': Fotemustine demonstrated improved response rates over [[~~dacarbazine~~]], ~~another drug commonly used in melanoma treatment~~.		Common side effects of fotemustine include [[myelosuppression]], which can lead to [[neutropenia]], [[thrombocytopenia]], and [[anemia]]. Patients may also experience [[nausea]], [[vomiting]], and [[fatigue]]. Due to its potential to cause severe [[bone marrow suppression]], blood counts are closely monitored during treatment.
	* '''Survival Rates''': Despite the improved response rates with fotemustine, ~~it did not significantly prolong overall survival when juxtaposed with dacarbazine~~. ~~Median survival times were 7.3 months for fotemustine as opposed~~ to ~~5.6 months for dacarbazine (DTIC) (P=.067)~~.

	=== ~~Safety~~ and ~~Toxicity Concerns ===~~		==Pharmacokinetics==
			Fotemustine is rapidly absorbed and distributed throughout the body after intravenous administration. It is metabolized in the liver and excreted primarily through the kidneys. The drug's ability to penetrate the blood-brain barrier is a significant advantage in treating brain metastases.

	The administration of fotemustine is not without its challenges. Patients undergoing treatment with fotemustine need vigilant monitoring due to notable toxicity profiles. Noteworthy findings from the aforementioned study<ref name=~~"study1"/> include:~~		==Related Pages==
	* ~~'''Neutropenia''': Fotemustine exhibited a notably higher incidence of grade 3 to 4 neutropenia, with 51% of patients presenting with this condition compared to just 5% in the dacarbazine group.~~		* [[Chemotherapy]]
	* '''Thrombocytopenia''': Thrombocytopenia, a condition where the blood has a lower than normal number of platelets, was another pronounced side effect. 43% of fotemustine-treated patients faced this complication compared to 6% in the dacarbazine group.		* [[Alkylating agent]]
			* [[Malignant melanoma]]
			* [[Brain tumor]]
			* [[Nitrosourea]]

	~~=== Regulatory Status and Availability ===~~		[[Category:Chemotherapy drugs]]
			[[Category:Alkylating agents]]
	While fotemustine has found its place in the European market, it remains unapproved by the U.S. FDA. This divergence in regulatory status underscores the importance of continuous research and evaluation in drug safety and efficacy. It also highlights the dynamic nature of the global regulatory environment, where a drug's acceptance in one jurisdiction doesn't guarantee its approval in another<ref>Article on global drug regulatory differences and considerations</ref>.

	~~=== Conclusion ===~~
	Fotemustine offers a potential therapeutic avenue for the management of metastatic melanoma. While its efficacy has been demonstrated in terms of response rates, concerns regarding its safety profile, particularly hematological toxicities, emphasize the importance of careful patient monitoring and consideration. As with many chemotherapeutic agents, the balance between efficacy and safety remains a crucial aspect of its clinical utilization.
	~~== References ==~~
	~~<references />~~
	~~{{Chemotherapeutic agents}}~~
	[[Category:~~Alkylating antineoplastic agents~~]]
	[[Category:~~Nitrosamines~~]]
	[[Category:Nitrosoureas]]		[[Category:Nitrosoureas]]
	~~[[Category:Organochlorides]]~~
	~~[[Category:Phosphonate esters]]~~
	~~[[Category:Ureas]]~~
	~~[[Category:Chloroethyl compounds]]~~
	~~{{antineoplastic-drug-stub}}~~
	~~{{nt}}~~

Prab at 02:35, 27 September 2023

2023-09-27T02:35:22Z

New page

[[File:Fotemustine.svg|thumb|Fotemustine]]
== Fotemustine: Therapeutic Role and Clinical Considerations ==
'''Fotemustine''' stands as a notable chemotherapeutic agent in the landscape of melanoma treatments, particularly for metastatic melanoma, one of the most aggressive and challenging forms of skin cancer. Classified as a [[nitrosourea alkylating agent]], fotemustine has drawn interest in the European medical community for its therapeutic potential, although it remains unapproved by the [[United States Food and Drug Administration|U.S. FDA]].

=== Mechanism of Action ===

As a nitrosourea alkylating agent, fotemustine exerts its cytotoxic effects by causing DNA damage. Specifically, it facilitates the formation of cross-links in DNA, hindering its replication and transcription, thereby inhibiting the proliferation of malignant cells<ref>Review article on the mechanism of nitrosourea alkylating agents</ref>.

=== Clinical Efficacy and Comparisons ===

Fotemustine's clinical worth has been explored in comparative studies with other established treatments for metastatic melanoma. A prominent study<ref name="study1">[2]</ref> revealed the following insights:
* '''Response Rates''': Fotemustine demonstrated improved response rates over [[dacarbazine]], another drug commonly used in melanoma treatment.
* '''Survival Rates''': Despite the improved response rates with fotemustine, it did not significantly prolong overall survival when juxtaposed with dacarbazine. Median survival times were 7.3 months for fotemustine as opposed to 5.6 months for dacarbazine (DTIC) (P=.067).

=== Safety and Toxicity Concerns ===

The administration of fotemustine is not without its challenges. Patients undergoing treatment with fotemustine need vigilant monitoring due to notable toxicity profiles. Noteworthy findings from the aforementioned study<ref name="study1"/> include:
* '''Neutropenia''': Fotemustine exhibited a notably higher incidence of grade 3 to 4 neutropenia, with 51% of patients presenting with this condition compared to just 5% in the dacarbazine group.
* '''Thrombocytopenia''': Thrombocytopenia, a condition where the blood has a lower than normal number of platelets, was another pronounced side effect. 43% of fotemustine-treated patients faced this complication compared to 6% in the dacarbazine group.

=== Regulatory Status and Availability ===

While fotemustine has found its place in the European market, it remains unapproved by the U.S. FDA. This divergence in regulatory status underscores the importance of continuous research and evaluation in drug safety and efficacy. It also highlights the dynamic nature of the global regulatory environment, where a drug's acceptance in one jurisdiction doesn't guarantee its approval in another<ref>Article on global drug regulatory differences and considerations</ref>.

=== Conclusion ===
Fotemustine offers a potential therapeutic avenue for the management of metastatic melanoma. While its efficacy has been demonstrated in terms of response rates, concerns regarding its safety profile, particularly hematological toxicities, emphasize the importance of careful patient monitoring and consideration. As with many chemotherapeutic agents, the balance between efficacy and safety remains a crucial aspect of its clinical utilization.
== References ==
<references />
{{Chemotherapeutic agents}}
[[Category:Alkylating antineoplastic agents]]
[[Category:Nitrosamines]]
[[Category:Nitrosoureas]]
[[Category:Organochlorides]]
[[Category:Phosphonate esters]]
[[Category:Ureas]]
[[Category:Chloroethyl compounds]]
{{antineoplastic-drug-stub}}
{{nt}}

Fotemustine - Revision history

Prab: CSV import

Prab at 02:35, 27 September 2023